Department of Chemistry, School of Natural Sciences, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea.
J Mater Chem B. 2021 Apr 14;9(14):3143-3152. doi: 10.1039/d0tb02850a. Epub 2021 Feb 22.
Drug resistance is a major cause of treatment failure for small-molecule cancer chemotherapies, despite the advances in combination therapies, drug delivery systems, epigenetic drugs, and proteolysis-targeting chimeras. Herein, we report the use of a drug resistance-free cytotoxic nanodrug as an alternative to small-molecule drugs. The present nanodrugs comprise 2 nm core gold nanoparticles (AuNPs) covered completely with multivalent hydrocarbon chains to a final diameter of ∼10 nm as single drug molecules. This hydrophobic drug-platform was delivered in composite form (∼35 nm) with block-copolymer like other small-molecular drugs. Upon uptake by cells, the nanodrugs enhanced the intracellular levels of reactive oxygen species and induced apoptosis, presumably reflecting multivalent interactions between aliphatic chains and intracellular biomolecules. No resistance to our novel nanodrug was observed following multiple treatment passages and the potential for use in cancer therapy was verified in a breast cancer patient-derived xenograft mouse model. These findings provide insight into the use of nano-scaled compounds as agents that evade drug resistance to cancer therapy.
尽管在联合治疗、药物输送系统、表观遗传药物和蛋白水解靶向嵌合体方面取得了进展,但耐药性仍是小分子癌症化疗治疗失败的主要原因。在此,我们报告了使用无耐药性细胞毒性纳米药物作为小分子药物的替代品。目前的纳米药物由 2nm 核金纳米粒子(AuNPs)组成,这些纳米粒子完全被多价烃链覆盖,最终直径约为 10nm,作为单一药物分子。这种疏水性药物平台以复合形式(约 35nm)与嵌段共聚物一起被递送至细胞内,类似于其他小分子药物。纳米药物被细胞摄取后,会增强细胞内活性氧的水平并诱导细胞凋亡,这可能反映了脂肪链与细胞内生物分子之间的多价相互作用。在多次治疗传代后,没有观察到对我们新型纳米药物的耐药性,并且在乳腺癌患者来源的异种移植小鼠模型中验证了其在癌症治疗中的应用潜力。这些发现为纳米尺度化合物作为逃避癌症治疗耐药性的药物提供了新的思路。